Veeda Clinical Research acquires European CRO ‘Heads’

New Delhi: Veeda Clinical Research Limited, a full-service contract research organization (CRO) has announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology.

Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch.

Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region.

The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets. India’s diverse demographic profile provides a unique opportunity to conduct clinical trials, especially in therapeutic areas including oncology, diabetes, hypertension, infectious diseases, and special diseases.

With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia Pacific. Veeda’s ever-growing relationship with large biopharma companies and access to KOL’s across multiple countries will accelerate execution of global clinical trials in both the western and eastern populations. In recent years, Veeda has added expertise in the late stage clinical and global trials for large molecules. High quality and efficient clinical trial execution remains the top priority for the clients of the combined entity.

Sharing details related to common synergies between Veeda and Heads, Dr Mahesh Bhalgat, Group – CEO of Veeda Clinical Research, said, “With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the Oncology research. This equips Veeda to build long and enduring site relationships across geographies.”

Elaborating on the prospects of this partnership, Binoy Gardi, Executive Vice Chairperson of Veeda Clinical Research, said, “As we integrate the operations of both the companies, this is an exciting opportunity for Veeda and Heads to expand markets, leverage complimentary capabilities and add value to our clients. We believe that our combined strengths will enable us to drive greater efficiency, innovation, and excellence in delivering research outcomes for drug development programs of our clients worldwide.”

“There is a very strong cultural fit between Heads and Veeda,” said Dr George Kouvatseas, Partner, Heads. “Both companies share a dedication to scientific leadership, expansion of highly specialized services to meet the emerging needs of our clients, an uncompromising focus on quality, and a belief that our strength is in our people and the way in which they work together.

During the integration phase, Heads will continue to offer uninterrupted support to client programs. The Veeda and Heads organization together are committed to nimble operations through a structured integration process without impact to ongoing client programs.”